GROWW (Guiding interdiciplinary Research On Women's and girl's health and Wellbeing) - Simon Fraser University

Informations complètes et à jour, compilées par Google Actualités à partir de sources d'actualité du monde entier

AbstractBackground & AimsElevated antimicrobial antibodies have been reported up to 6 years before diagnosis of Crohn’s disease (CD), but the specific antibody response is unclear. Here, we characterized the antimicrobial antibody responses before CD diagnosis in healthy first-degree relatives (FDRs) of patients with CD. MethodsThe CCC-GEM (Crohn’s and Colitis Canada – Genetic, Environmental, Microbial) Project nested case-control cohort consisted of FDRs who later developed CD (n = 77), matched 1:4 by age, sex, follow-up duration, and geographical location with healthy FDRs (n = 304). Sera at enrollment were probed for antimicrobial reactivity using a microbiota antigen microarray and a flagellin peptide cytometric bead array. Conditional logistic regression was used to assess association with CD onset, and partial Spearman was used to correlate serologic responses with lactulose-to-mannitol ratio (LMR), C-reactive protein (CRP), and fecal calprotectin (FCP). False discovery rate was controlled using the Benjamini-Hochberg method (q < 0.05).

The rapid-access cancer care program Same Day/Next Day (SDND) served a higher proportion of patients with high socioeconomic risk for poor outcomes than the traditional health care path, and more socially vulnerable patients initiated therapy, according to results presented at the 19th AACR Conference on The Science of Cancer Health Disparities, held Oct. 18–21 in Atlanta. "Delay in care is one of the largest negative predictors of cancer outcomes," said Joseph P. Flemming, D. O., from Jefferson Abington Hospital, who presented the study. "The SDND program rapidly connects patients with expert guidance to support them in navigating the beginning of their cancer journey. "